



COUNTRY PROFILE

Germany

EDCTP participation



Germany in EDCTP

(2003-present)

Germany in EDCTP: key figures

Since 2003, institutions from Germany have contributed to EDCTP-funded research through sustained participation, project coordination, and wide international collaboration.



125

projects involving German institutions or fellows



37

German institutions involved in EDCTP-funded projects



61

collaborating countries with German entities through EDCTP-funded projects



32

consortia-based **projects coordinated** by German institutions



€74.5 M

EDCTP funding attributed to German entities



353

international partner institutions collaborating with German entities*


M = million

**Distinct non-German institutions participating in EDCTP-funded projects that include at least one German entity*

Germany in EDCTP: participation over time

Germany's participation has continued across EDCTP iterations, showing a long-term engagement that extends into the current Global Health EDCTP3 programme.

Germany - participation across EDCTP iterations




TMA = Training and Mobility Action; **RIA** = Research and Innovation Action; **CSA** = Coordination and Support Action. EDCTP1 used 10 original funding categories, which were regrouped here under TMA, RIA and CSA equivalents for over-time comparability. In Global Health EDCTP3, CSAs may include fellowship components, but not direct individual fellowship grants as under the TMA model in EDCTP 1 and 2

Germany in EDCTP: participating organisations

Germany's participation in EDCTP-funded projects has been led by academic and clinical research hubs, complemented by product-development and private-sector actors.

Top 20 Germany-based entities by EDCTP funding amounts




Germany in EDCTP: international collaboration

Since 2003, Germany's EDCTP collaboration network has spanned 59 countries, with strong links across Africa and Europe.

61 collaborating countries: **39** in Africa | **15** in Europe | 7 in other world regions

Top 20 partner countries by number of shared EDCTP-funded projects



Geographical spread of Germany's EDCTP collaboration links



Germany's wider contribution to EDCTP

Beyond project participation, Germany supports EDCTP through financial contributions and aligned in-kind activities that advance EDCTP objectives.

€43.1 M in-cash contribution

Germany's contribution to the EDCTP Association, 2016-2025

€356.3 M aligned in-kind investments

Value of Germany's in-kind activities aligned with EDCTP Programme objectives

Aligned in-kind activities

Supporting ecosystem development

- *African health research networks*: over €100 M to support 36 African and 12 German partners across 13 countries, strengthening disease research and clinical/laboratory capacity.
- *Global Health Protection Programme*: nearly €100 M supporting public health systems, research capacity and epidemic preparedness.

Scaling up technologies

- *Product development partnerships*: around €30 M supporting vaccines, diagnostics, medicines, and prevention tools for neglected diseases.
- *Coalition for Epidemic Preparedness Innovations (CEPI)*: around €100 M supporting faster vaccine development and access for emerging infectious disease outbreaks.

Impact example: paediatric schistosomiasis treatment

Through Merck KGaA, Germany's participation helped advance **Arpraziquantel**, the first schistosomiasis medicine designed for young children.

Story

Merck KGaA, a German pharmaceutical company, worked with international partners to develop Arpraziquantel, a child-friendly treatment for schistosomiasis.

What changed

EDCTP-supported trial evidence showed that Arpraziquantel was safe and effective for children aged 3 months to 6 years, supporting a positive EMA opinion, WHO prequalification, and its inclusion in WHO's Essential Medicines List.

Why this matters

Schistosomiasis affects 240 million people worldwide and can cause lifelong disability and death. Arpraziquantel could help protect up to 50 million at-risk children.

[More info here](#)



WHO-prequalified



EMA positive opinion

EDCTP's contribution included:

- ✓ support to the clinical development and plans for large-scale access and delivery of Arpraziquantel
- ✓ support to capacity development and networks

[Child-friendly arpraziquantel for paediatric schistosomiasis](#)



Impact example: rapid TB diagnosis

Through LMU Munich, Germany's participation helped test rapid **molecular TB diagnosis** in primary care, generating evidence for faster treatment initiation closer to patients.

Story

The EDCTP-funded TB-CAPT project evaluated new TB diagnostic strategies in real-life health system settings. LMU Munich led the TB-CAPT CORE trial pillar, testing portable Truenat assays in primary care facilities in Tanzania and Mozambique.

What changed

The trial showed that decentralised Truenat testing brought molecular TB diagnosis closer to patients. Among confirmed TB patients, 96.7% in Truenat clinics started treatment within 7 days, compared with 63.3% under standard care. Same-day treatment initiation increased from 3.3% to 82.2%.

Why this matters

Faster diagnosis means earlier treatment, reducing severe disease, onward transmission, and the risk that patients do not return for care before treatment starts.

EDCTP's contribution included:

- ✓ funding for pragmatic, real-world implementation research
- ✓ support to test a WHO-endorsed diagnostic platform in primary care settings
- ✓ evidence to guide national TB programmes on decentralised molecular diagnosis

*The Lancet Primary Care, 2025
PLOS Global Public Health, 2025*



WHO-recommended



Partnership spotlight

Professor Peter Kremsner's EDCTP prize highlights a long-standing Germany-Gabon research partnership around CERMEL and infectious disease research.



Prof. Peter Kremsner

Tropical diseases researcher

University of Tübingen | CERMEL, Lambaréné

CERMEL as a research hub

Contributed to the development of CERMEL as a major Gabon-based centre for infectious disease research.

Recognised by EDCTP

Received the 2023 **EDCTP Dr Pascoal Mocumbi Prize**, which recognises outstanding achievements in health research and capacity development in Africa.

Collaborative infectious disease R&I

Supported clinical research on malaria, hookworm, tuberculosis and Ebola, including vaccine studies conducted through CERMEL.

Training through partnership

Contributed to doctoral training and scientific mentorship, supporting research careers across African and international collaborations.

Read the story: Professor Peter Kremsner receives the prestigious EDCTP Dr Pascoal Mocumbi Prize →



EDCTP project highlight

A German partner contributed to the TB-Child Consortium, generating much needed evidence on tools to diagnose Tuberculosis (TB) in children.

TB-CHILD was an EDCTP-funded consortium (2010–2013) that addressed one of the greatest challenges in tuberculosis control: **diagnosing TB in children**.

The consortium generated evidence supporting the **WHO recommendation of Xpert MTB/RIF for paediatric TB diagnosis** and pioneered the promising TAM-TB blood-based assay, a sputum-independent test capable of distinguishing active from latent TB.

The project brought together partners from **seven countries, including Germany**, helping to advance innovative diagnostics while strengthening the evidence base for child-friendly TB diagnosis in sub-Saharan Africa.

The project also received **co-funding** from the German Federal Ministry of Education and Research.

Pediatric TB diagnosis



EDCTP project highlight

A German partner contributed to the PEP4LEP study on post-exposure prophylaxis for leprosy.

PEP4LEP was an EDCTP2-funded implementation project (2018–2024) established to identify **the most effective and cost-effective approach for preventing leprosy through post-exposure prophylaxis** in sub-Saharan Africa.

The project compared **community-based "skin camps"** with health facility-based screening to detect leprosy and other skin diseases, generating evidence to guide national and global implementation of preventive strategies while reducing delays in diagnosis and stigma.

The consortium brought together partners from Ethiopia, Germany, Mozambique, the Netherlands, and Tanzania, with the **German Leprosy and Tuberculosis Relief Association (DAHJ)** helping strengthen integrated skin disease management and leprosy prevention in endemic communities.




Germany in Global Health EDCTP3

(2021-present)

Germany in Global Health EDCTP3: key figures

Since 2021, Germany has been one of Global Health EDCTP3’s most active participants, with strong coordination roles, broad international collaboration, and substantial grant funding.

45	13	26	52	26	€32.69 M	€36.7 M
funded projects with Germany participation	projects coordinated by German entities	German entities participating in funded projects	countries collaborating with German entities through funded projects	German experts evaluating project proposals	grant funding to German entities participating in projects	total project costs for German entities participating in projects




Grant funding attributed to Global Health EDCTP3 participating entities, by country


Germany in Global Health EDCTP3: key figures

Germany's participation has been driven mainly by universities and research organisations, alongside a smaller but visible contribution from private for-profit entities.

German participating entities by type



German participating entities by grant amounts



* Types of organisations in this chart follow the taxonomy used by the European Commission and Horizon Europe programme.


Germany in Global Health EDCTP3: collaboration network

Since 2021, German entities have collaborated with partners in 52 countries across Europe, Africa, and beyond through Global Health EDCTP3 projects.

Geographical distribution of Germany's collaboration links



Top 15 collaborations with Germany in funded projects (number of links)



Governance and advisory input

Germany contributes to Global Health EDCTP3 governance and advisory structures through the EDCTP Association, Scientific Committee, and Stakeholders' Group.

ADVISORY

5

Germany-affiliated members and representatives in the Scientific Committee and Stakeholders' Group

Ahmed Abd el Wahed

Scientific Committee
Leipzig University, Germany

DSW,

Deutsche Stiftung Weltbevölkerung
Stakeholders' Group
Lisa Goerlitz | Ffion Storer Jones

Robert Koch Institute

Stakeholders' Group
Prof. Dr Johanna Hanefeld |
Dr Heide Weishaar

GOVERNANCE

2

Germany-affiliated representatives in the EDCTP Association General Assembly

Dr Henning Gädeke

General Assembly
German Federal Ministry of Research,
Technology and Space

Dr Jeannette Endres-Becke

General Assembly
DLR Joint Ventures GmbH



Since
2014



Germany has been part of
the EDCTP Association

Project highlight: ComBac-Africa

A Germany-based university coordinates a project improving access to new antibiotics and incorporating measures to limit drug resistance.

The challenge:

- Limited access to effective antibiotics and high resistance in hospital pathogens.
- Weak diagnostics and infection control drive misuse of antibiotics and faster antimicrobial resistance.

Expected impact:

- Enhance access to a group of new antibiotics in Côte d'Ivoire, Guinea-Bissau, and Nigeria.
- Promote stronger hospital infection prevention and antibiotic stewardship programmes.



Coordinator:
Universität des Saarlandes, Germany

Countries: **Germany, Nigeria, Portugal, Guinea-Bissau, Côte d'Ivoire, South Africa, Switzerland**

Funding: **€5.9 M**

Project length: **2025 – 2029**

https://www.global-health-edctp3.europa.eu/projects/combac-africa_en



Project highlight: eWHORM

A Germany-based university coordinates a project assessing the efficacy of the oxfendazole against different parasitic worm infections.

The challenge:

- Soil-transmitted helminths affect 1.5 billion people and cause a major but neglected disease burden.
- Current treatments are limited and resistance is rising, with a lack of new drugs.

Expected impact:

- Conduct a multi-country clinical trial of oxfendazole across several parasitic worm infections, testing different doses and co-infections.
- Introduce rapid molecular diagnostics (LAMP) and training tools for parasite detection and trial implementation.



Coordinator:

Universitätsklinikum Bonn, Germany

Countries: **Germany, Austria, DRC, Cameroon, Netherlands, Gabon, Switzerland**

Funding: **€8.0 M**

Project length: **2023 – 2028**

https://www.global-health-edctp3.europa.eu/projects/ewhorm_en

Project highlight: PRESERVE

A German partner contributes to the preparedness, research, and surveillance network for infectious diseases in Central Africa.

The challenge:

- Central Africa is highly vulnerable to emerging infections.
- Preparedness is constrained by weak infrastructure, limited expertise, and poor cross-border data sharing.

Expected impact:

- Build regional One Health and clinical research capacity across Central Africa.
- Develop tools, protocols, and systems to rapidly launch outbreak clinical trials.
- Upgrade laboratories, training, and infrastructure to improve preparedness.



Coordinator:

European & Developing Countries Clinical Trials Partnership, Netherlands

Scientific leader:

Fondation Congolaise Pour La Recherche Medicale, Congo

Countries: **Netherlands, Congo, France, Cameroon, DRC, Germany, UK, Gabon, Zambia**

Funding: **€12.5 M** with additional €1.6 M by EDCTP Association members and contributing partners

Project length: **2026 – 2031**

https://www.global-health-edctp3.europa.eu/projects/preserve_en

Thank you!

Global Health EDCTP3



Co-funded by
the European Union

